Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

149
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
149
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

193
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
193
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

163
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
163
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

167
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
167
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

520
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
520
Regulation of Stroke Volume01:27

Regulation of Stroke Volume

4.5K
The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALDH18A1 fuels spermine biosynthesis to sustain ferroptosis resistance in cancer and ischemia-reperfusion injury.

Cell cycle (Georgetown, Tex.)·2026
Same author

Circulating Extracellular Mitochondria Perpetuate Endothelial Damage via Cardiolipin-Mediated Mitophagic Overload.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Decoding the molecular memory of obesity using machine learning and microRNA dynamics.

The Journal of physiology·2026
Same author

From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling.

Cardiovascular diabetology. Endocrinology reports·2026
Same author

Epicardial fat enhances prediction of exercise-induced hypertension and ventricular arrhythmias in asymptomatic normotensive individuals.

European journal of internal medicine·2026
Same author

A proteomic atlas phenotyping Fabry disease identifies a precise cardiovascular risk signature that integrates mitochondrial and lysosomal pathways.

Journal of molecular medicine (Berlin, Germany)·2026

Related Experiment Videos

Stroke prevention: Learning from the master (and COMMANDER).

Gaetano Santulli1

  • 1Department of Medicine, Albert Einstein College of Medicine, Montefiore University Hospital, New York, NY 10461, USA; Department of Advanced Biomedical Sciences, "Federico II" University, Naples, 80131, Italy. gsantulli001@gmail.com.

Science Translational Medicine
|April 30, 2019
PubMed
Summary
This summary is machine-generated.

Adding rivaroxaban to standard heart failure treatment did not reduce the risk of death in patients without atrial fibrillation. This study found no significant benefit for this specific patient group.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Heart failure is a major cause of mortality.
  • Atrial fibrillation is a common comorbidity in heart failure.
  • Anticoagulants like rivaroxaban are used in some heart failure patients.

Purpose of the Study:

  • To investigate the efficacy of rivaroxaban in reducing mortality in heart failure patients without atrial fibrillation.
  • To evaluate the safety and effectiveness of adding rivaroxaban to standard care in this population.

Main Methods:

  • A randomized controlled trial was conducted.
  • Patients with heart failure and no atrial fibrillation received standard therapy plus rivaroxaban or placebo.
  • The primary endpoint was all-cause mortality.

Main Results:

  • Adding rivaroxaban to standard therapy did not significantly decrease the risk of death.
  • No significant differences in major adverse cardiovascular events were observed between groups.
  • The safety profile was comparable between the rivaroxaban and placebo groups.

Conclusions:

  • Rivaroxaban is not beneficial for reducing death risk in patients with heart failure and no atrial fibrillation.
  • Current guidelines for anticoagulation in heart failure should be considered for this specific patient subgroup.